Completed PHASE3 INTERVENTIONAL 1-arm NCT00171821

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload

Sponsor: Novartis Pharmaceuticals

Conditions Transfusion-dependent Iron Overload

Interventions Deferasirox

Updated 7 times since 2017 Last updated: Feb 8, 2020 Started: Apr 30, 2005 Primary completion: May 31, 2009 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00171821, this PHASE3 trial focuses on Transfusion-dependent Iron Overload and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Mar 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Mar 2020 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Adana, Turkey (Türkiye) , Adelaide, Australia , Afula, Israel , Angers, France , Ankara, Turkey (Türkiye) , Athens, Greece , Augsburg, Germany , Avignon, France , Bangkok, Thailand and 87 more locations